A systematic review of interventions in the early course of bipolar disorder I or II: a report of the International Society for Bipolar Disorders Taskforce on early intervention.
Antipsychotics
Bipolar disorder
CBT
Course
Depression
Early intervention
Lithium
Mania
Mood stabilisers
Psychoeducation
Recurrence
Remission
Systematic review
Journal
International journal of bipolar disorders
ISSN: 2194-7511
Titre abrégé: Int J Bipolar Disord
Pays: Germany
ID NLM: 101622983
Informations de publication
Date de publication:
03 Jan 2023
03 Jan 2023
Historique:
received:
22
09
2022
accepted:
14
11
2022
entrez:
3
1
2023
pubmed:
4
1
2023
medline:
4
1
2023
Statut:
epublish
Résumé
Given the likelihood of progressive illness in bipolar disorder (BD), it is important to understand the benefits and risks of interventions administered early in illness course. We conducted a systematic review of the effectiveness of interventions in the early course of BD I or II. We completed a systematic search on MEDLINE, PsycINFO, EMBASE, the Cochrane Central Register of Controlled Trials, CINAHL and Google Scholar from 1/1/1979 till 14/9/2022. We included controlled trials examining intervention effects on symptomatic, course, functional and tolerability outcomes of patients in the 'early course' of BD I or II. We classified patients to be in early course if they (a) were seeking help for the first time for a manic episode, (b) had a lifetime history of up to 3 manic episodes, or (c) had up to 6 lifetime mood episodes. Evidence quality was assessed using the GRADE approach. From 4135 unique publications we included 25 reports representing 2212 participants in 16 randomized studies, and 17,714 participants from nine non-randomized studies. Available evidence suggested that in early illness course, lithium use was associated with lower recurrence risk compared with other mood stabilizers. Mood stabilizers were also associated with better global functioning, compared with the use of antipsychotics in the medium term. While summative findings regarding psychological therapies were limited by heterogeneity, family-focused and cognitive-behavioral interventions were associated with reduced recurrence risk or improved symptomatic outcomes. There was some evidence that the same pharmacological interventions were more efficacious in preventing recurrences when utilized in earlier rather than later illness course. While there are promising initial findings, there is a need for more adequately powered trials to examine the efficacy and tolerability of interventions in youth and adults in early illness course. Specifically, there is a compelling need to compare the relative benefits of lithium with other pharmacological agents in preventing recurrences. In addition to symptomatic outcomes, there should be a greater focus on functional impact and tolerability. Effective pharmacological and psychological interventions should be offered to those in early course of BD, balancing potential risks using shared decision-making approaches.
Sections du résumé
BACKGROUND
BACKGROUND
Given the likelihood of progressive illness in bipolar disorder (BD), it is important to understand the benefits and risks of interventions administered early in illness course. We conducted a systematic review of the effectiveness of interventions in the early course of BD I or II.
METHODS
METHODS
We completed a systematic search on MEDLINE, PsycINFO, EMBASE, the Cochrane Central Register of Controlled Trials, CINAHL and Google Scholar from 1/1/1979 till 14/9/2022. We included controlled trials examining intervention effects on symptomatic, course, functional and tolerability outcomes of patients in the 'early course' of BD I or II. We classified patients to be in early course if they (a) were seeking help for the first time for a manic episode, (b) had a lifetime history of up to 3 manic episodes, or (c) had up to 6 lifetime mood episodes. Evidence quality was assessed using the GRADE approach.
RESULTS
RESULTS
From 4135 unique publications we included 25 reports representing 2212 participants in 16 randomized studies, and 17,714 participants from nine non-randomized studies. Available evidence suggested that in early illness course, lithium use was associated with lower recurrence risk compared with other mood stabilizers. Mood stabilizers were also associated with better global functioning, compared with the use of antipsychotics in the medium term. While summative findings regarding psychological therapies were limited by heterogeneity, family-focused and cognitive-behavioral interventions were associated with reduced recurrence risk or improved symptomatic outcomes. There was some evidence that the same pharmacological interventions were more efficacious in preventing recurrences when utilized in earlier rather than later illness course.
CONCLUSIONS AND RECOMMENDATIONS
CONCLUSIONS
While there are promising initial findings, there is a need for more adequately powered trials to examine the efficacy and tolerability of interventions in youth and adults in early illness course. Specifically, there is a compelling need to compare the relative benefits of lithium with other pharmacological agents in preventing recurrences. In addition to symptomatic outcomes, there should be a greater focus on functional impact and tolerability. Effective pharmacological and psychological interventions should be offered to those in early course of BD, balancing potential risks using shared decision-making approaches.
Identifiants
pubmed: 36595095
doi: 10.1186/s40345-022-00275-3
pii: 10.1186/s40345-022-00275-3
pmc: PMC9810772
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1Subventions
Organisme : NIMH NIH HHS
ID : R01 MH123575
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Psychol Med. 2014 Dec;44(16):3455-67
pubmed: 25066366
Acta Psychiatr Scand. 2019 Aug;140(2):94-115
pubmed: 31218667
Am J Psychiatry. 2006 Feb;163(2):240-6
pubmed: 16449477
Bipolar Disord. 2011 Feb;13(1):87-98
pubmed: 21320256
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Gen Hosp Psychiatry. 2013 Nov-Dec;35(6):664-7
pubmed: 23988234
Bipolar Disord. 2014 Aug;16(5):548-56
pubmed: 24127825
Int J Bipolar Disord. 2019 Mar 27;7(1):10
pubmed: 30915592
Lancet. 2013 Nov 9;382(9904):1575-86
pubmed: 23993280
Acta Neuropsychiatr. 2010 Apr;22(2):50-3
pubmed: 25385029
Acta Psychiatr Scand. 2013 Sep;128(3):179-93
pubmed: 23379960
Bipolar Disord. 2020 May;22(3):231-244
pubmed: 31730294
Lancet Psychiatry. 2021 Jan;8(1):64-75
pubmed: 32857954
JAMA Netw Open. 2020 Apr 1;3(4):e203221
pubmed: 32315069
Am J Psychiatry. 2018 May 1;175(5):411-426
pubmed: 29361850
J Physiol Paris. 2013 Sep;107(4):278-85
pubmed: 23542544
World J Biol Psychiatry. 2010 Mar;11(2):81-109
pubmed: 20148751
Bipolar Disord. 2018 Mar;20(2):97-170
pubmed: 29536616
J Am Acad Child Adolesc Psychiatry. 2015 Mar;54(3):217-24
pubmed: 25721187
J Child Adolesc Psychopharmacol. 2021 Sep;31(7):485-493
pubmed: 34520250
J Affect Disord. 2014 Jan;152-154:403-8
pubmed: 24268595
Soc Psychiatry Psychiatr Epidemiol. 2005 Feb;40(2):106-13
pubmed: 15685401
Br J Psychiatry Suppl. 1998;172(33):53-9
pubmed: 9764127
BMJ. 2008 Apr 26;336(7650):924-6
pubmed: 18436948
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
World J Biol Psychiatry. 2013 Apr;14(3):154-219
pubmed: 23480132
BMC Med. 2013 Jul 11;11:162
pubmed: 23844755
Am J Psychiatry. 1999 Aug;156(8):1264-6
pubmed: 10450271
Br J Psychiatry. 2008 Feb;192(2):150-1
pubmed: 18245035
World J Biol Psychiatry. 2009;10(2):85-116
pubmed: 19347775
Eur Psychiatry. 2015 Nov;30(8):975-82
pubmed: 26485297
JAMA Psychiatry. 2018 Jun 1;75(6):555-565
pubmed: 29800949
Am J Psychiatry. 1994 Jan;151(1):130-2
pubmed: 8267112
Harv Rev Psychiatry. 2003 Sep-Oct;11(5):245-56
pubmed: 14555425
Am J Psychiatry. 2014 Jun;171(6):658-67
pubmed: 24626789
Mol Psychiatry. 2016 Aug;21(8):1050-6
pubmed: 26460229
Int J Neuropsychopharmacol. 2014 Oct 31;18(2):
pubmed: 25522415
Bipolar Disord. 2004 Oct;6(5):406-15
pubmed: 15383133
Psychol Med. 2021 May 26;:1-8
pubmed: 34034840
J Psychopharmacol. 2016 Jun;30(6):495-553
pubmed: 26979387
Bipolar Disord. 2015 Mar;17(2):128-38
pubmed: 25346391
J Clin Psychiatry. 2006 Jan;67(1):95-101
pubmed: 16426094
Arch Gen Psychiatry. 2008 Sep;65(9):1053-61
pubmed: 18762591
Br J Psychiatry. 2006 Apr;188:313-20
pubmed: 16582056
Acta Psychiatr Scand. 1986 Jan;73(1):60-7
pubmed: 3962704
J Am Acad Child Adolesc Psychiatry. 2020 Oct;59(10):1146-1155
pubmed: 31369795
Bipolar Disord. 2017 Nov;19(7):524-543
pubmed: 28944987
Lancet Psychiatry. 2019 Oct;6(10):869-876
pubmed: 31248840
Bipolar Disord. 2017 Dec;19(8):627-636
pubmed: 29268003
Arch Gen Psychiatry. 2003 Sep;60(9):904-12
pubmed: 12963672
Biol Psychiatry. 2003 Jun 1;53(11):1028-42
pubmed: 12788248
BMJ. 1999 Jan 16;318(7177):149-53
pubmed: 9888904
Neurosci Biobehav Rev. 2011 Jan;35(3):804-17
pubmed: 20934453
Br J Psychiatry. 2017 Jun;210(6):413-421
pubmed: 28254958
J Psychopharmacol. 2012 May;26(5):644-52
pubmed: 21948935
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Br J Psychiatry. 2014 Sep;205(3):214-20
pubmed: 25012681
Bull N Y Acad Med. 1994 Winter;71(2):300-6
pubmed: 19313108
Bipolar Disord. 2016 Sep;18(6):490-501
pubmed: 27647671
Br J Psychiatry. 2013 Mar;202(3):212-9
pubmed: 23349295
J Am Acad Child Adolesc Psychiatry. 2016 Dec;55(12):1038-1045.e4
pubmed: 27871638
Bipolar Disord. 2021 Nov;23(7):659-678
pubmed: 34174130
Early Interv Psychiatry. 2012 Nov;6(4):380-8
pubmed: 22225628
Int J Bipolar Disord. 2014 Dec 20;2:15
pubmed: 25530932
J Affect Disord. 2007 Nov;103(1-3):181-6
pubmed: 17324469
Bipolar Disord. 2021 Jun;23(4):341-356
pubmed: 33030292
Stat Med. 2005 May 30;24(10):1455-81
pubmed: 15586395
BMJ. 2020 Jan 16;368:l6890
pubmed: 31948937
Aust N Z J Psychiatry. 2021 Jan;55(1):7-117
pubmed: 33353391
Br J Psychiatry. 2011 Jul;199(1):57-63
pubmed: 21593515